Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of liraglutide in combination with metformin versus metformin monotherapy on glycaemic control in children and adolescents with type 2 diabetes

Next Previous
Trial Profile

Efficacy and safety of liraglutide in combination with metformin versus metformin monotherapy on glycaemic control in children and adolescents with type 2 diabetes

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Liraglutide (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms Ellipse
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 25 Sep 2020 Results of post hoc analysis assessing weight-related parameters presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
    • 04 Sep 2020 Results of post hoc analysis evaluating effect of liraglutide treatment on weight parameters in children and adolescents with type 2 diabetes, presented at the 2020 European and International Congress on Obesity
    • 28 Jun 2019 According to an European Medicines Agency media release, the EMA's human medicines committee (CHMP) has recommended granting an extension of indication to Victoza (liraglutide) to include the treatment of children and adolescents aged 10 years or older with type 2 diabetes. The CHMP opinion will now be sent to the European Commission for the adoption of a decision on an EU-wide marketing authorisation.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top